Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
12 competitors in Multiple Myeloma
No patent data available. Pre-approval drugs may not have Orange Book listings.
Ninlaro
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Fabry Disease
Type 2 Diabetes Mellitus
Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Disease
Hypertension